32.49

14.99% 4.235

After Hours: 32.32 -0.175 -0.54%

Cue Biopharma Inc (CUE)

Overview News Price History Option Chain Financials Discussions Forecast

Cue Biopharma Inc stock is traded at $32.49, with a volume of 127.67K. It is up +14.99% in the last 24 hours and up +10.30% over the past month. Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Previous Close:

$28.26

Open:

$28.01

24h Volume:

127.67K

Relative Volume:

0.18

Market Cap:

$136.49M

Revenue:

$32.73M

Net Income/Loss:

$-19.52M

P/E Ratio:

-5.8788

EPS:

-5.5275

Net Cash Flow:

$-24.61M

1W Performance:

+6.79%

1M Performance:

+10.30%

6M Performance:

+195.06%

1Y Performance:

+55.81%

1-Day Range:

$28.01

$34.18

1-Week Range:

$27.25

$35.05

52-Week Range:

$4.971

$41.42

Cue Biopharma Inc Stock (CUE) Company Profile

Name

Cue Biopharma Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617-949-2680

Address

40 GUEST STREET, BOSTON, MA

Employee

Twitter

@cuebiopharma

Next Earnings Date

2026-08-11

Latest SEC Filings

CUE's Discussions on Twitter

Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CUE Cue Biopharma Inc	32.49	132.56M	32.73M	-19.52M	-24.61M	-5.5275
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-24	Initiated	Jefferies	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Nov-21-22	Initiated	Piper Sandler	Overweight
Jan-13-22	Initiated	H.C. Wainwright	Buy
Jan-03-22	Initiated	Craig Hallum	Buy
Nov-24-20	Initiated	Berenberg	Buy
Apr-09-20	Initiated	Stifel	Buy
Jan-28-20	Initiated	BTIG Research	Buy
Jan-22-20	Initiated	JMP Securities	Mkt Outperform

View All

Cue Biopharma Inc Stock (CUE) Latest News

Jul 02, 2026

[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan

Jul 02, 2026

Jun 30, 2026

CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits

Jun 30, 2026

Jun 29, 2026

Signal Law Group Issues VRS Bulletin on Cue Biopharma, Inc. (CUE) - The Daily Tribune News

Jun 29, 2026

Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits

Jun 28, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Cue Biopharma, Inc. – LS:A426PN - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Cue Biopharma, Inc. – LS:A426PN - TradingView

Jun 26, 2026

Jun 25, 2026

Cue Biopharma Company Profile & Introduction - Moomoo

Jun 25, 2026

Price to earnings forward of Cue Biopharma, Inc. – LS:A426PN - TradingView

Jun 25, 2026

Price to sales forward of Cue Biopharma, Inc. – LS:A426PN - TradingView

Jun 25, 2026

Jun 24, 2026

Long term debt to total equity ratio of Cue Biopharma, Inc. – LS:A426PN - TradingView

Jun 24, 2026